HeraMED Limited provide an update on the trial of its smart medical grade foetal heart rate monitor HeraBEAT, and its cloud based SaaS pregnancy monitoring platform HeraCARE PRO, with one of Brazil's largest healthcare providers Hapvida Saude (Hapvida). Following the successful integration of HeraCARE PRO into Hapvida's IT systems (refer ASX announcement: 1 July 2019), HeraMED advises that its HeraBEAT devices and the Company's HeraCARE PRO platform are now operational at multiple locations and being utilised by medical professionals and patients as part of a broader pilot trial. Hapvida is one of Brazil's largest healthcare providers and medical insurance companies. The group services over 6.5 million customers annually, through a network of over 100 hospitals and 1,000 clinics across 11 states. HeraMED is now witnessing seamless data upload and sharing between the operational HeraBEAT monitors and the customised HeraCARE PRO platform from Hapvida. This development outlines the potential scalability of both solutions and further validates the Company's potential with large scale medical organisations. Both Hapvida and HeraMED remain in ongoing discussions regarding ongoing platform updates and optimisation. Both parties will aim to utilise the solutions during the intrapartum phase of pregnancy, which is the period spanning childbirth, from the onset of labour. Should this be successful, it will provide even greater value to the platform and potentially underpin increased uptake. HeraMED will remain in ongoing discussions with Hapvida's medical professionals to gather feedback on the HeraBEAT device and HeraCARE solution. The Company will update shareholders as developments associated with the trial progress.